Stock AnalizDexCom Inc. DXCM
Medical/Dental Instruments · IPO 2005 · data as of November 13, 2026
DexCom Inc. (DXCM) is a healthcare company listed in the US with a market value of about $31.1B. In the twelve months to September 30, 2026 it had revenue of $5.1B and net income of $991M, a net margin of 19.4%.
Its overall Stock Analiz score is 3.4 out of 5 (good). The strongest part is future growth (5/5); the weakest is value (0/5).
Key numbers: a P/E of 32.8, a price to free cash flow of 28.3, 5-year revenue growth of 19% a year, a 5-year average ROIC of 16%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 41% below the current price.
Score: 3.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 5-year EPS growth above 10% a year
- Pays a dividend
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1B | $4.7B | $4.0B | $3.6B | $2.9B | $2.4B | $1.9B | $1.5B | $1.0B | $718M | $573M |
| Net income | $991M | $836M | $576M | $542M | $341M | $217M | $550M | $101M | -$127M | -$50M | -$66M |
| Free cash flow | $1.1B | $1.1B | $631M | $512M | $305M | $53M | $277M | $134M | $56M | $26M | $500000 |
| EPS (diluted) | $2.54 | $2.09 | $1.42 | $1.30 | $0.82 | $0.53 | $1.33 | $0.28 | $-0.36 | $-0.15 | $-0.20 |
| Net margin | 19.4% | 17.9% | 14.3% | 14.9% | 11.7% | 8.9% | 28.5% | 6.9% | -12.3% | -7.0% | -11.4% |
| ROIC | — | 24.7% | 14.4% | 21.0% | 11.3% | 10.4% | 14.2% | 14.2% | -20.9% | -8.0% | -17.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 26 analysts is $98.58, 18% above the current price; targets range from $79.00 to $120.00; the consensus rating is “Strong buy”; expected EPS is $2.70 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is DexCom’s P/E ratio?
About 32.8, based on the last twelve months of diluted earnings per share (forward P/E about 28.5).
Is DexCom stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 41% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does DexCom pay a dividend?
Not currently.
Is DexCom a good stock to buy?
We do not give buy or sell advice. DexCom scores 3.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.